Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.40 |
| ▸ | TK2 | O00142 | 6/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536270 | 0.90 | TK1 (0.39) | TK1TK2TYMP | |
| SCHEMBL2112758 | 0.89 | TYMP (0.40) | TK1TYMP | |
| SCHEMBL2711193 | 0.88 | TK1 (0.39) | TK1TK2TYMP | |
| SCHEMBL8592454 | 0.87 | RNASE1 (0.44) | TK1TK2TYMP | |
| SCHEMBL9294173 | 0.86 | TYMP (0.37) | TK1TK2TYMP | |
| SCHEMBL7084173 | 0.86 | TK2 (0.38) | TK1TK2TYMP | |
| SCHEMBL1594780 | 0.84 | TK1 (0.35) | TK1TK2TYMP | |
| SCHEMBL315534 | 0.82 | TYMP (0.51) | TK1TK2TYMP | |
| SCHEMBL5888977 | 0.82 | TYMP (0.51) | TK1TK2TYMP | |
| SCHEMBL31723482 | 0.82 | TYMP (0.51) | TK1TK2TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735364-B2 | Antisense modulation of apolipoprotein B expression | GENZYME CORPORATION (US) | 2014-05-27 | — | — | US | disclosed |
| US-8492355-B2 | — | — | 2013-07-23 | — | — | US | disclosed |
| US-20080242629-A1 | Hybrid nucleic acids; controlling gene expression; metabolism disorders, obesity, diabetes | ISIS PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7002006-B2 | Protection of nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-6884787-B2 | Antisense modulation of transforming growth factor-beta 3 expression | ISIS PHARMACEUTICALS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040158055-A1 | Protection of nucleosides | IONIS PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6602857-B1 | Antisense modulation of PTP1B expression | ISIS PHARMACEUTICALS, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20030078217-A1 | Antisense modulation of transforming growth factor-beta 3 expression | ISIS PHARMACEUTICALS INC. | 2003-04-24 | — | — | US | disclosed |
| US-6524854-B1 | Modulation of the expression of the PKA regulatory RII subunit alpha may provide a means of regulating the expression of PKA; modulation of its activity is a potential strategy with which to treat metabolic or developmental disorders | ISIS PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6498035-B1 | METHODS ARE PROVIDED FOR MODULATING THE EXPRESSION OF MEKK3. THE COMPOSITIONS COMPRISE ANTISENSE COMPOUNDS, PARTICULARLY ANTISENSE OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS ENCODING MEKK3. | ISIS PHARMACEUTICALS, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6440737-B1 | POLYPEPTIDES | ISIS PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6200807-B1 | COMPOUND 8 TO 30 NUCLEOBASES IN LENGTH TARGETED TO REGULATORY OR CODING SEQUENCES OF HUMAN NON-MEMBRANE TYROSINE PHOSPHATASE; DIAGNOSIS, THERAPY, AND PROPHYLAXIS OF RELATED DISORDERS | ISIS PHARMACEUTICALS INC. | 2001-03-13 | — | — | US | disclosed |
| US-6008048-A | AN OLIGONUCLEOTIDE FOR MODULATING EXPRESSION OF AN EARLY GROWTH RESPONSE-1 PROTEIN; CHELATING/EMULSIFYING AGENTS; ANTITUMOR/ANTIINFLAMMATORY/ANTICARCINOGENIC AGENTS; SURFACTANTS | ISIS PHARMACEUTICALS INC. (US) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158055-A1 | Protection of nucleosides | RNASEL, ADAR, RNGTT | TK1 54/4885TK2 259/4885TYMP 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.